Hjem › Crohns sykdom
Kliniske studier for Crohns sykdom rekrutterer i USA
93 studier for Crohns sykdom rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- New York City, NY35 studier
- Cleveland, OH19 studier
- St. Louis, MO19 studier
- Boston, MA19 studier
- Miami, FL19 studier
- Orlando, FL17 studier
- Houston, TX17 studier
- Atlanta, GA17 studier
- Tyler, TX16 studier
- San Diego, CA15 studier
- San Antonio, TX15 studier
- Los Angeles, CA15 studier
- Philadelphia, PA13 studier
- Colorado Springs, CO13 studier
- Durham, NC12 studier
- Providence, RI12 studier
- Tacoma, WA11 studier
- Pittsburgh, PA11 studier
- Cincinnati, OH11 studier
- Seattle, WA11 studier
- Baltimore, MD10 studier
- Washington, DC10 studier
- Indianapolis, IN10 studier
- Dallas, TX10 studier
- Lubbock, TX10 studier
- Tampa, FL10 studier
- Ann Arbor, MI9 studier
- Chicago, IL9 studier
- Louisville, KY9 studier
- Evanston, IL9 studier
- Lewisville, TX9 studier
- Rochester, MN8 studier
- Parma, OH8 studier
- New Haven, CT8 studier
- Columbus, OH8 studier
- Charlotte, NC8 studier
- Independence, MO8 studier
- Milwaukee, WI7 studier
- Lafayette, LA7 studier
- Queens, NY7 studier
Etter delstat
- Alabama9 studier
- Arizona17 studier
- Arkansas3 studier
- California37 studier
- Colorado18 studier
- Connecticut14 studier
- District of Columbia4 studier
- Florida27 studier
- Georgia22 studier
- Idaho4 studier
- Illinois18 studier
- Indiana13 studier
- Iowa8 studier
- Kansas11 studier
- Kentucky12 studier
- Louisiana11 studier
- Maryland15 studier
- Massachusetts27 studier
- Michigan20 studier
- Minnesota11 studier
- Mississippi3 studier
- Missouri21 studier
- Nevada8 studier
- New Hampshire3 studier
- New Jersey9 studier
- New York36 studier
- North Carolina20 studier
- Ohio30 studier
- Oklahoma8 studier
- Oregon4 studier
- Pennsylvania23 studier
- Rhode Island12 studier
- South Carolina11 studier
- South Dakota4 studier
- Tennessee10 studier
- Texas35 studier
- Utah8 studier
- Virginia15 studier
- Washington22 studier
- Wisconsin7 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
RekruttererObservasjonsstudie
Alder 18 til 85 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07619547Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekruttererFase 3
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07697456Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07033208Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07852273A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RekruttererFase 4
Alder 18 til 80 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06581328Non-nutritive Sweeteners in Inflammatory Bowel Disease
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 70 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07769437A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05923073Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RekruttererFase 3
Alder 3 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06663332A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RekruttererFase 3
Alder 18 til 70 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06937099Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
Rekrutterer
Alder 16 til 75 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT07671872Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
RekruttererFase 3
Alder 2 til 17 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05995353A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RekruttererFase 2
Alder 18 til 85 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RekruttererFase 3
Alder 2 til 19 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT04844606A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RekruttererFase 4
Alder 18 til 70 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06045754Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.